Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2)

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 176-183

  Sahni, A ^a,c   Simpson haidaris, P J ^a   Sahni, S K ^a   Vaday, G G ^b   Francis, C W ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

FGF 2; Fibrinogen; PC 3; Prostate cancer; RNAi

Indexed keywords

DNA; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 2; THYMIDINE; TRITIUM;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; FIBRINOGEN SYNTHESIS; FLUOROGRAPHY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; LUNG ADENOCARCINOMA; MALE; MUTANT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN INTERACTION; RNA INTERFERENCE; WILD TYPE;

CELL PROLIFERATION; DRUG SYNERGISM; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 37549035033     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02808.x     Document Type: Article

References (57)

1. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16: 179-86.
2. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11: 709-24.
3. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-78.
4. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, Basilico C, Ittmann M. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63: 5754-60.
5. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3: 887-93.
6. Levin EG, Sikora L, Ding L, Rao SP, Sriramarao P. Suppression of tumor growth and angiogenesis in vivo by a truncated form of 24-kd fibroblast growth factor (FGF)-2. Am J Pathol 2004; 164: 1183-90.
7. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 2001; 93: 1783-90.
8. Berger W, Setinek U, Mohr T, Kindas-Mugge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C, Micksche M. Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 1999; 83: 415-23.
9. Nakamoto T, Chang CS, Li AK, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992; 52: 571-7.
10. Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002; 21: 5733-42.
11. Akashi T, Minami J, Ishige Y, Eishi Y, Takizawa T, Koike M, Yanagishita M. Basement membrane matrix modifies cytokine interactions between lung cancer cells and fibroblasts. Pathobiology 2005; 72: 250-9.
12. Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H. Anti-tumor angiogenesis therapy using soluble receptors: Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 2002; 9: 633-40.
13. Hantgan RR, Simpson-Haidaris PJ, Francis CW, Marder VJ. Fibrinogen structure and physiology. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 203-32.
14. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-9.
15. Rokhlin OW, Cohen MB. Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate 1995; 26: 205-12.
16. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993; 119: 637-44.
17. Trikha M, Timar J, Lundy SK, Szekeres K, Tang K, Grignon D, Porter AT, Honn KV. Human prostate carcinoma cells express functional alphaIIb(beta)3 integrin. Cancer Res 1996; 56: 5071-8.
18. Dedhar S, Saulnier R, Nagle R, Overall CM. Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metastasis 1993; 11: 391-400.
19. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004; 92: 185-90.
20. Al-Mondhiry H, Drago J, Bartholomew MJ. The fibrinolytic system in experimental prostate tumor. Thromb Haemost 1986; 56: 133-6.
21. Sahni A, Francis CW. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires αvβ3. Blood 2004; 104: 3635-41.
22. Sahni A, Odrljin T, Francis CW. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem 1998; 273: 7554-9.
23. Sahni A, Sporn LA, Francis CW. Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J Biol Chem 1999; 274: 14936-41.
24. Sahni A, Baker CA, Sporn LA, Francis CW. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost 2000; 83: 736-41.
25. Sahni A, Altland OD, Francis CW. FGF-2 but not FGF-1 binds fibrin and supports prolonged endothelial cell growth. J Thromb Haemost 2003; 1: 1304-10.
26. Sahni A, Francis CW. Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J Thromb Haemost 2003; 1: 1271-7.
27. Sahni A, Khorana AA, Baggs RB, Peng H, Francis CW. FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood 2006; 107: 126-31.
28. Bunce LA, Sporn LA, Francis CW. Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the β chain. J Clin Invest 1992; 89: 842-50.
29. Peng H, Sahni A, Fay P, Bellum S, Prudovsky I, Maciag T, Francis CW. Identification of a binding site on human FGF-2 for fibrinogen. Blood 2004; 103: 2114-20.
30. Simpson-Haidaris PJ. Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells. Blood 1997; 89: 873-82.
31. Odrljin TM, Rybarczyk BJ, Francis CW, Lawrence SO, Hamaguchi M, Simpson-Haidaris PJ. Calcium modulates plasmin cleavage of the fibrinogen D fragment β chain N-terminus: Mapping of monoclonal antibody J88B to a plasmin sensitive domain of the β chain. Biochim Biophys Acta 1996; 1298: 69-77.
32. Lawrence SO, Simpson-Haidaris PJ. Regulated de novo biosynthesis of fibrinogen in extrahepatic epithelial cells in response to inflammation. Thromb Haemostas 2004; 92: 234-43.
33. Redman CM, Xia H. Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion. Ann N Y Acad Sci 2001; 936: 480-95.
34. Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-33.
35. Ploplis VA, Wilberding J, McLennan L, Liang Z, Cornelissen I, DeFord ME, Rosen ED, Castellino FJ. A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am J Pathol 2000; 157: 703-8.
36. Rybarczyk BJ, Lawrence SO, Simpson-Haidaris PJ. Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. Blood 2003; 102: 4035-43.
37. Kaminski A, Hahne JC, Haddouti el M, Florin A, Wellmann A, Wernert N. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts. Int J Mol Med 2006; 18: 941-50.
38. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999; 59: 1655-64.
39. Odrljin TM, Haidaris CG, Lerner NB, Simpson-Haidaris PJ. Integrin αvβ3-mediated endocytosis of immobilized fibrinogen by A549 lung alveolar epithelial cells. Am J Respir Cell Mol Biol 2001; 24: 12-21.
40. Sahni A, Sahni SK, Simpson-Haidaris PJ, Francis CW. Fibrinogen binding potentiates FGF-2 but not VEGF induced expression of u-PA, u-PAR, and PAI-1 in endothelial cells. J Thromb Haemost 2004; 2: 1629-36.
41. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin distribution in malignant melanoma: Association of the β3 subunit with tumor progression. Cancer Res 1990; 50: 6757-64.
42. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-2.
43. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. Multiple roles for platelet GPIIb/IIIa and αvβ3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002; 62: 2824-33.
44. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli R, Cheresh DA. Vascular integrin αvβ3: A new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4: 2625-34.
45. Geng JG. Interaction of vascular endothelial cells with leukocytes, platelets and cancer cells in inflammation, thrombosis and cancer growth and metastasis. Acta Pharmacol Sin 2003; 24: 1297-300.
46. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM. αvβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 2003; 63: 2079-87.
47. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62: 6966-72.
48. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: The molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006; 32: 54-70.
49. Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003; 62: 1078-82.
50. Simpson-Haidaris PJ, Rybarczyk BJ. Tumors and fibrinogen: The role of fibrinogen as an extracellular matrix protein. Ann NY Acad Sci 2001; 936: 406-25.
51. Guadiz G, Sporn LA, Simpson-Haidaris PJ. Thrombin cleavage-independent deposition of fibrinogen in extracellular matrices. Blood 1997; 90: 2644-53.
52. Rybarczyk BJ, Simpson-Haidaris PJ. Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Cancer Res 2000; 60: 2033-9.
53. Lee SY, Lee KP, Lim JW. Identification and biosynthesis of fibrinogen in human uterine cervix carcinoma cells. Thromb Haemostas 1996; 75: 466-70.
54. Molmenti EP, Ziambaras T, Perlmutter DH. Evidence for an acute phase response in human intestinal epithelial cells. J Biol Chem 1993; 268: 14116-24.
55. Pentecost BT, Bradley LM, Gierthy JF, Ding Y, Fasco MJ. Gene regulation in an MCF-7 cell line that naturally expresses an estrogen receptor unable to directly bind DNA. Mol Cell Endocrinol 2005; 238: 9-25.
56. Tan YJ, Tham PY, Chan DZ, Chou CF, Shen S, Fielding BC, Tan TH, Lim SG, Hong W. The severe acute respiratory syndrome coronavirus 3a protein up-regulates expression of fibrinogen in lung epithelial cells. J Virol 2005; 79: 10083-7.
57. Rescher U, Danielczyk A, Markoff A, Gerke V. Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells. J Immunol 2002; 169: 1500-4.